Shrestha, R.; Prithviraj, P.; Bridle, K.R.; Crawford, D.H.G.; Jayachandran, A.
Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. J. Clin. Med. 2021, 10, 1889.
https://doi.org/10.3390/jcm10091889
AMA Style
Shrestha R, Prithviraj P, Bridle KR, Crawford DHG, Jayachandran A.
Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. Journal of Clinical Medicine. 2021; 10(9):1889.
https://doi.org/10.3390/jcm10091889
Chicago/Turabian Style
Shrestha, Ritu, Prashanth Prithviraj, Kim R. Bridle, Darrell H. G. Crawford, and Aparna Jayachandran.
2021. "Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment" Journal of Clinical Medicine 10, no. 9: 1889.
https://doi.org/10.3390/jcm10091889
APA Style
Shrestha, R., Prithviraj, P., Bridle, K. R., Crawford, D. H. G., & Jayachandran, A.
(2021). Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. Journal of Clinical Medicine, 10(9), 1889.
https://doi.org/10.3390/jcm10091889